OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Dr. Strickler on the Efficacy of Tucatinib/Trastuzumab in HER2+ Colorectal Cancer

July 16th 2022

John H. Strickler, MD, discusses the efficacy of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Shitara on the Rationale for the DESTINY-Gastric04 Trial in HER2+ Gastric Cancers

July 16th 2022

Kohei Shitara, MD, discusses the rationale for the phase 3 DESTINY-Gastric04 trial in patients with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma.

Dr. Brahmer on the Examination of Nemvaleukin Alfa in Solid Tumors

July 16th 2022

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

Dr. Waks on the Continued Evaluation of Immunotherapy in HER2+ Breast Cancer

July 14th 2022

Adrienne G. Waks, MD, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

Dr. Porcu on the Need for Diverse Representation in Clinical Trials

July 14th 2022

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Dr. Kalinsky on Ovarian Function Suppression and Chemotherapy in HR–Positive Breast Cancer

July 14th 2022

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

Dr. Brahmer on the 5-Year Data for Nivolumab/Ipilimumab in NSCLC

July 14th 2022

Julie R. Brahmer, MD, MSc, discusses the significance of the long-term survival data of nivolumab plus ipilimumab seen in the phase 3 CheckMate-227 trial in patients with metastatic non–small cell lung cancer.

Dr. Paz-Ares on Nivolumab/Ipilimumab Plus Chemotherapy in NSCLC

July 14th 2022

Luis G. Paz-Ares, MD, PhD, discuses the importance of nivolumab plus ipilimumab in the treatment of patients with metastatic non–small cell lung cancer.

Dr. Simon on the Evaluation of Datopotamab Deruxtecan in TROP-2–Expressing Solid Tumors

July 13th 2022

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

Dr. Kim on the Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

July 13th 2022

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

Dr. Peled on the Rationale of Evaluating Lenvatinib/Pembrolizumab with Chemotherapy in NSCLC

July 13th 2022

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Dr Han on the Significance of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

July 13th 2022

Heather Han, MD, discusses breakthrough data from the phase 3 DESTINY-Breast04 trial.

Dr. Jain on Potential Biomarkers in HR-Positive, HER2-Negative Breast Cancer

July 13th 2022

Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr. Desai on Expanding Options for Cisplatin-Ineligible Bladder Cancer

July 13th 2022

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.

Dr. Ross on the Rise of Colon and Rectal Cancer in Young Patients

July 12th 2022

Howard M. Ross, MD, discusses the increase in colon and rectal cancer in young patients.

Dr. Bidard on the Importance of Elacestrant in ER+/HER2- Breast Cancer

July 12th 2022

Francois-Clement Bidard, MD, PhD, discusses the importance of elacestrant in estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.

Dr. Sandhu on Findings with Niraparib in Metastatic Prostate Cancer

July 12th 2022

Shahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.

Dr. Barata on the Challenges of Treating Advanced Urothelial Carcinoma

July 11th 2022

Pedro C. Barata, MD, MSc, discusses challenges associated with treating advanced urothelial carcinoma.

Dr. Hays on Treatment Options in HER2-Positive CRC

July 11th 2022

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.